Dupilumab: dramatic improvement in a patient with severe Atopic dermatitis. About a case
DOI:
https://doi.org/10.29176/2590843X.1704Keywords:
Atopic dermatitis, Depression, Dupilumab, TreatmentAbstract
The case of a 25-year-old woman with a diagnosis of severe atopic dermatitis from 6 months of age, desquamative erythematous variety, with involvement greater than 90% of the body surface, and recurrent, severe, and difficult-to-control symptoms, resistant to systemic steroids and immunosuppressants, is presented. Filaggrin mutation was documented. Additionally, she developed major depression, with three suicide attempts. Considering the refractoriness to the treatment, the associated comorbidities, and the decrease in quality of life, it was decided to start management with dupilumab, with the fourth dose of the drug there was a dramatic improvement evaluated by standardized severity indices (EASI, SCORAD, POEM, DLQI) for disease. The patient achieved control of the disease from the beginning of the drug, being able to quickly dismantle steroids and even presented gradual improvement in her depression, with dismantling of antidepressant treatment.
Author Biographies
Valentina Arango, Estudiante de pregrado medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
Estudiante de pregrado medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
Ana María Garavito, Estudiante de pregrado medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
Estudiante de pregrado medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
Liliana María Tamayo, Médica, Dermatóloga-Alergóloga, Clínica Universitaria Bolivariana; docente, Facultad de Medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
Médica, Dermatóloga-Alergóloga, Clínica Universitaria Bolivariana; docente, Facultad de Medicina, Universidad Pontificia Bolivariana, Medellín, Colombia.
References
Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345-60. https://doi.org/10.1016/S0140-6736(20)31286-1
Laughter MR, Maymone MBC, Mashayekhi S, Arents BWM, Karimkhani C, Langan SM, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017. Br J Dermatol. 2021;184(2):304-9. https://doi. org/10.1111/bjd.19580
Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, et al. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: a cross-sectional study. BMC Pulm Med. 2012;12(1):17. https://doi.org/10.1186/1471-2466-12-17
Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136-43. https://doi.org/10.1056/NEJMra2023911
Tamayo Quijano LM, Montoya Guarín CJ, Salgado Vélez H, Cardona Villa R. Conceptos básicos, clínicos y terapéuticos de la dermatitis atópica. Rev Asoc Colomb Dermat Cir Dermatol. 2003;11(1):13-28. Disponible en: https://bit.ly/3rMvKwS
Ordoñez CP, Tamayo LM, Gamboa LA, Pradilla MT, Hernández Mantilla N, Candía MPN, et al. Guía de práctica clínica (GPC) para el diagnóstico y tratamiento de la dermatitis atópica en Colombia. Rev Asoc Colomb Dermatol Cir Dermatol. 2018;1-250. Disponible en: https://bit.ly/3JnoM7f
Ring J, Alomar A, Bieber T, Deleuran M, Fink-Wagner A, Gelmetti C, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. J Eur Acad Dermatology Venereol. 2012;26(9):1176-93. https://doi.org/10.1111/j.1468-3083.2012.04636.x
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, Deleuran M, Fink-Wagner A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatology Venereol. 2018;32(5):657-82. http://doi.org/10.1111/jdv.14891
Ferreira S, Torres T. Dupilumab for the Treatment of Atopic Dermatitis. Actas Dermosifiliográficas (Eng Ed). 2018;109(3):230-40. https://doi. org/10.1016/j.ad.2017.10.012
Strowd LC, Feldman SR. Dupilumab for atopic dermatitis. Lancet. 2017;389(10086):2265-6. https://doi.org/10.1016/S0140-6736(17)31192-3
Guttman-Yassky E, Bissonnette R, Ungar B, Suárez-Fariñas M, Ardeleanu M, Esaki H, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155-72. https://doi.org/10.1016/j.jaci.2018.08.022
Regeneron Pharmaceuticals Inc. Dupixent® (dupilumab) Prescribing information. 2021 [citado el 4 de noviembre de 2021]; Disponible en: https:// bit.ly/3Jn1rCD
Silverberg JI, Yosipovitch G, Simpson EL, Kim BS, Wu JJ, Eckert L, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. J Am Acad Dermatol. 2020;82(6):1328-36. https://doi.org/10.1016/j.jaad.2020.02.060
Regeneron Pharmaceuticals Inc. FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma. 2021 [citado el 4 de noviembre de 2021]. Disponible en: https://bit.ly/33fdGBQ
Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375(24):2335-48. http://doi.org/10.1056/NEJMoa1610020
How to Cite
Downloads
Downloads
Published
How to Cite
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
